Actively Recruiting
Open-label Study Comparing Dovramilast Doses to Standard Treatments for Moderate to Severe Leprosy Type 2 Reaction
Led by Medicines Development for Global Health · Updated on 2026-11-03
45
Participants Needed
6
Research Sites
78 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the experimental drug dovramilast in adults with moderate to severe acute or recurrent leprosy type 2 reaction, also known as erythema nodosum leprosum ENL. This phase 2 study compares the safety and effectiveness of two doses of dovramilast 100 mg and 150 mg against standard treatments such as prednisolone or thalidomide. The study aims to assess skin lesion improvement and the incidence of side effects over a 12-week period. Participants will be randomly assigned to receive either 100 mg or 150 mg of dovramilast or the standard of care treatment. The study is open-label, meaning both participants and researchers know which treatment is given. Treatment lasts 12 weeks, with outcomes measured at this timepoint, including the degree of skin lesion improvement and safety events. The study also monitors fever resolution, neuropathy changes, and recurrence of symptoms over up to 48 weeks. During the study, participants will undergo regular assessments including skin evaluations, symptom scoring using the ENLIST severity scale, and laboratory tests to monitor health and side effects. Researchers will track the need for rescue medication and measure drug exposure levels. Participants are expected to comply with all study procedures, including photographic assessments of skin lesions. The total participation time may extend to 48 weeks for some outcome measurements and safety monitoring.
CONDITIONS
Brief Title
Efficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here